Britain’s biggest company AstraZeneca (AZN) has paused a planned $271.26M investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Britain, Reuters’ Alistair Smout and Maggie Fick report. The decision on the investment, which had been set to create 1,000 jobs, means none of the AstraZeneca’s planned new funding – originally announced in March 2024 – is currently proceeding. U.S. drugmaker Merck (MRK) also said this week that it was abandoning a new research center in London, citing the U.K.’s challenging business environment, the authors add.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Trump officials to link COVID shots to child deaths, WaPo reports
- AstraZeneca’s OLIVIA Study: Advancing Ovarian Cancer Care in Brazil
- AstraZeneca announces EMA validation for Enhertu marketing authorization
- Advertising, drugmaker stocks in spotlight as Trump moves to regulate pharma ads
- Omnicom, WPP under pressure after Trump moves to regulate pharma ads